Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01743898 · ClinicalTrials.gov registry record
A Prospective Pharmacodynamic Study of Rivaroxaban
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 65
- Enrollment target
NCT01743898 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 65 participants.
The verdict
NCT01743898 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic doses of rivaroxaban may be helpful in better understanding abnormal responses to rivaroxaban. The purpose of the study is to define a therapeutic reference range for peak and trough coagulation tests in patients taking FDA approved doses of rivaroxaban and to determine which tests may be most clinically useful for monitoring rivaroxaban.
Interventions
- DRUG Rivaroxaban
- OTHER no anticoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01743898
The ClinicalTrials.gov registry entry for NCT01743898 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban is the first listed.
NCT01743898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01743898 about?
NCT01743898 is a clinical study titled "A Prospective Pharmacodynamic Study of Rivaroxaban". The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic d...
What is the current status of trial NCT01743898?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01743898?
The interventions under investigation include: Rivaroxaban (DRUG), no anticoagulation (OTHER).
Who is sponsoring clinical trial NCT01743898?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.